AGIO
HealthcareAgios Pharmaceuticals, Inc. · Biotechnology · $2B
What is Agios Pharmaceuticals, Inc.?
Agios Pharmaceuticals is a biopharmaceutical company focused on cellular metabolism, developing targeted therapies for rare blood disorders. Headquartered in Cambridge, Massachusetts, the company is advancing a pipeline centered on pyruvate kinase activation.
Agios discovers and develops medicines that target cellular metabolism and adjacent biology. Its commercial product, PYRUKYND (mitapivat), activates pyruvate kinase enzymes — both wild-type and mutant forms — to treat hemolytic anemias. The company also has AG-946 in early-stage clinical development for hemolytic anemias and potentially other indications. Revenue is driven primarily by PYRUKYND's commercial launch and ongoing clinical milestones.
Agios was incorporated in 2007 and is based in Cambridge, Massachusetts.
- PYRUKYND (mitapivat) — approved treatment for hemolytic anemias
- AG-946 — Phase I clinical candidate for hemolytic anemias
- Pyruvate kinase activation platform targeting rare blood diseases
- Cellular metabolism research pipeline
Is AGIO a Good Stock to Buy?
UQS Score rates AGIO as Below Average overall, reflecting meaningful gaps across several fundamental pillars.
The Growth pillar stands out as the clearest positive — Agios is expanding its commercial footprint with PYRUKYND and advancing its pipeline, suggesting meaningful top-line momentum. The Risk pillar also registers as Good, indicating the company's risk profile is relatively manageable for a clinical-stage biopharmaceutical.
Quality and Moat both score Weak, pointing to limited earnings durability and a narrow competitive position typical of early-commercial biotechs. Valuation is Elevated, meaning the market may already be pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AGIO pay dividends?
No — Agios Pharmaceuticals, Inc. does not currently pay a dividend.
Agios does not currently pay a dividend. This is common for clinical-stage and early-commercial biopharmaceutical companies, which typically reinvest available capital into research, development, and commercial expansion rather than returning cash to shareholders. Investors in AGIO are generally seeking growth from pipeline advancement rather than income.
When does AGIO report earnings?
Agios Pharmaceuticals reports earnings on a quarterly cadence, consistent with US-listed public companies.
Quarterly results for Agios tend to reflect PYRUKYND's commercial ramp alongside ongoing R&D investment. Investors watch closely for updates on net product revenue, cash runway, and pipeline progress — particularly AG-946 trial readouts.
For the most recent quarter's results and guidance, visit Agios Pharmaceuticals' investor relations page directly.
AGIO Price History
-52.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Agios Pharmaceuticals, Inc.?
Based on Agios Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AGIO Long-term Outlook
Agios's Strong Growth pillar suggests the company is on a meaningful upward trajectory, driven by PYRUKYND's commercial expansion and a broadening clinical pipeline. However, the Elevated Valuation pillar indicates that much of this anticipated growth may already be reflected in the current share price. The Good Risk rating provides some reassurance, but the Weak Quality and Moat pillars are reminders that profitability and competitive defensibility remain works in progress for this stage of the company.
Growth drivers
- Continued commercial uptake of PYRUKYND across hemolytic anemia indications
- Pipeline advancement of AG-946 into later clinical stages
- Potential label expansions or new indications for the pyruvate kinase platform
Key risks
- Elevated valuation leaves limited margin of safety if growth disappoints
- Weak moat means competitive threats from larger biopharmaceutical players are real
- Clinical and regulatory risk inherent to early-stage pipeline assets like AG-946
AGIO vs Peers
Agios operates in a competitive rare-disease biopharmaceutical landscape alongside several other clinical and commercial-stage companies.
Zymeworks focuses on multi-specific biotherapeutics for oncology, contrasting with Agios's metabolic and hematology focus.
Mineralys targets aldosterone-driven cardiovascular and cardiorenal diseases, a distinct therapeutic area from Agios's rare blood disorder pipeline.
Mesoblast develops cell-based therapies for inflammatory and cardiovascular diseases, representing a different biological approach than Agios's small-molecule metabolism platform.
Frequently Asked Questions
What does Agios Pharmaceuticals do?
Agios Pharmaceuticals discovers and develops medicines targeting cellular metabolism, with a focus on rare blood disorders. Its lead commercial product, PYRUKYND (mitapivat), activates pyruvate kinase enzymes to treat hemolytic anemias. The company also has AG-946 in Phase I clinical development for similar indications.
Does AGIO pay dividends?
No, Agios does not currently pay a dividend. Like most early-commercial biopharmaceutical companies, Agios reinvests capital into research, development, and commercialization efforts rather than distributing cash to shareholders.
When does AGIO report earnings?
Agios reports earnings on a quarterly basis, in line with standard US public company practice. For exact dates and the most recent results, check the investor relations section of the Agios Pharmaceuticals website.
Is AGIO a good stock to buy?
UQS Score rates AGIO as Below Average overall. The Growth pillar is Strong and Risk is Good, but Quality and Moat are both Weak, and Valuation is Elevated. Whether it fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is AGIO overvalued?
The UQS Valuation pillar for AGIO is rated Elevated, suggesting the current market price may already reflect a significant amount of future growth expectations. Investors should weigh this against the company's early-commercial stage and ongoing pipeline risk.
How does AGIO compare to its competitors?
Agios competes in the rare-disease biopharmaceutical space alongside companies like Zymeworks, Mineralys Therapeutics, and Mesoblast. Each pursues different therapeutic areas and biological approaches. Agios is differentiated by its pyruvate kinase activation platform and its focus on hemolytic anemias. Full UQS comparisons are available on each company's page.
What is AGIO's market cap bracket?
Agios Pharmaceuticals is classified as a mid-cap company. This places it in a range that typically reflects an established but still-growing business — larger than most early-stage biotechs but smaller than major pharmaceutical companies.
Who founded Agios Pharmaceuticals?
Agios Pharmaceuticals was founded by scientists with deep expertise in cellular metabolism, including connections to academic research at major institutions. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Detailed founding history is widely available through public sources.
Is AGIO a long-term quality investment?
From a long-term quality perspective, AGIO's UQS profile shows a mixed picture. The Strong Growth pillar is encouraging, but Weak Quality and Moat scores indicate the company has not yet built durable earnings power or a wide competitive moat. Long-term investors should monitor pipeline progress and commercial execution closely.
What is the main competitive advantage of Agios Pharmaceuticals?
Agios's primary differentiation lies in its pyruvate kinase activation platform — a scientifically distinct approach to treating hemolytic anemias. PYRUKYND is the first approved therapy of its kind for certain patient populations, giving Agios a first-mover position in a niche but underserved rare-disease market.
What sector does AGIO belong to?
Agios Pharmaceuticals operates in the Healthcare sector, specifically within biopharmaceuticals. The company focuses on rare hematological diseases driven by metabolic dysfunction, placing it in the rare-disease and specialty pharma segment of the broader healthcare market.
Is AGIO a growth stock or value stock?
Based on its UQS profile, AGIO leans toward growth. The Growth pillar is rated Strong, reflecting meaningful commercial and pipeline expansion. However, the Elevated Valuation pillar suggests the market has already priced in much of that growth, making it less of a traditional value opportunity.
Unlock Full AGIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for AGIO
- ✓Access detailed financial metrics and quality indicators
- ✓Compare AGIO against sector peers side by side
- ✓Track Growth and Risk pillar changes over time
- ✓Get the full analyst-grade view on valuation and moat
- ✓Screen for stocks with stronger Quality and Moat profiles
Pro Analysis
AGIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 36.6 | 1.3 | 36.0 | 81.3 | 73.7 | 0.0 | +0.3 |
| May 10, 2026 | 36.3 | 0.0 | 36.0 | 81.3 | 73.7 | 0.0 | -0.3 |
| May 3, 2026 | 36.6 | 1.3 | 36.0 | 81.3 | 73.7 | 0.0 | -0.1 |
| May 2, 2026 | 36.7 | 1.7 | 36.0 | 81.3 | 73.7 | 0.0 | 0.0 |
| May 1, 2026 | 36.7 | 1.7 | 36.0 | 81.3 | 73.6 | 0.0 | -0.1 |
| Apr 2, 2026 | 36.8 | 1.7 | 36.0 | 81.3 | 74.3 | 0.0 | — |
AGIO — Pillar Breakdown
Quality
— 1.3/100 (25%)Agios Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 81.3/100 (20%)Agios Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.7/100 (15%)Agios Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Agios Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 36/100 (25%)Agios Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AGIO.
Score Composition
Financial Data
More Stock Analysis
How is the AGIO UQS Score Calculated?
The UQS (Unified Quality Score) for Agios Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Agios Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Agios Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.